T1	pharmacokinetics 104 119	bioavailability
T2	drug 123 154	17 alpha-ethinylestradiol (EE2)
T3	mealTime 155 160	after
T4	frequency 163 169	single
T5	mode 170 174	oral
T6	dosage 193 206	50 micrograms
T7	drug 207 210	EE2
T8	pharmacokinetics 239 255	pharmacokinetics
T9	drug 259 262	EE2
T10	studyType 282 316	open, randomized, cross-over study
T11	drug 31 47	ethinylestradiol
T12	population 326 347	13 healthy volunteers
T13	food 380 390	herbal tea
T14	food 394 410	grapefruit juice
T15	food 4 20	grapefruit juice
T16	component 412 420	naringin
T17	dosage 422 431	887 mg/ml
T18	food 449 459	herbal tea
T19	food 461 477	grapefruit juice
T20	interaction 478 487	increased
T21	pharmacokinetics 48 63	bioavailability
T22	pharmacokinetics 519 523	Cmax
T23	value 539 546	to 137%
T24	value 554 571	range 64% to 214%
T25	interaction 589 598	increased
T26	pharmacokinetics 603 613;640 645	area under curve
T27	pharmacokinetics 665 668	AUC
T28	value 673 680	to 128%
T29	value 688 705	range 81% to 180%
T30	food 742 758	grapefruit juice
T31	interaction 759 768	increases
T32	pharmacokinetics 773 792	bioavailable amount
T33	drug 796 799	EE2
T34	food 80 96	grapefruit juice
T35	food 836 852	grapefruit juice
T36	interaction 853 861	inhibits
T37	pharmacokinetics 866 887	metabolic degradation
T38	drug 891 894	EE2
T39	interaction 908 917	increased
T40	pharmacokinetics 918 933	bioavailability
T41	drug 937 940	EE2
T42	food 951 967	grapefruit juice
A1	valence T31 Augmentation
A2	valence T25 Augmentation
A3	valence T20 Augmentation
A4	valence T39 Augmentation
R1	metabolism_decrease Arg1:T30 Arg2:T33	
R2	metabolism_decrease Arg1:T35 Arg2:T38	
R3	metabolism_decrease Arg1:T42 Arg2:T41	
